---
layout: default
title: Bempedoic Acid
description: "Bempedoic Acid çš„è€è—¥æ–°ç”¨æ½›åŠ›åˆ†æã€‚æ¨¡å‹é æ¸¬ç­‰ç´š L5ï¼ŒåŒ…å« 10 å€‹é æ¸¬é©æ‡‰ç—‡ã€‚æŸ¥çœ‹ AI é æ¸¬èˆ‡è‡¨åºŠè­‰æ“šå®Œæ•´å ±å‘Šã€‚"
parent: åƒ…æ¨¡å‹é æ¸¬ (L5)
nav_order: 29
evidence_level: L4
indication_count: 10
---

# Bempedoic Acid

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
è­‰æ“šç­‰ç´š: <strong>L5</strong> | é æ¸¬é©æ‡‰ç—‡: <strong>10</strong> å€‹
</p>

---

<div id="pharmacist">

## è—¥å¸«è©•ä¼°å ±å‘Š

</div>

# Bempedoic Acidï¼šå¾é«˜è†½å›ºé†‡åˆ°åŒåˆå­å®¶æ—æ€§é«˜è†½å›ºé†‡è¡€ç—‡

## ä¸€å¥è©±ç¸½çµ
<p class="key-answer" data-question="Bempedoic Acid å¯ä»¥ç”¨æ–¼æ²»ç™‚ä»€éº¼æ–°é©æ‡‰ç—‡ï¼Ÿ">
Bempedoic acid æ˜¯ ATP æª¸æª¬é…¸è£‚è§£é…¶æŠ‘åˆ¶åŠ‘ï¼Œç”¨æ–¼é™ä½ LDL-Cï¼ŒTxGNN é æ¸¬å…¶å°åŒåˆå­å®¶æ—æ€§é«˜è†½å›ºé†‡è¡€ç—‡ (HoFH) æœ‰é¡å¤–åƒ¹å€¼ï¼Œæ­¤é æ¸¬å·²ç²æ–‡ç»å¼·åŠ›æ”¯æŒã€‚
</p>

## å¿«é€Ÿç¸½è¦½
| é …ç›® | å…§å®¹ |
|------|------|
| åŸé©æ‡‰ç—‡ | åŸç™¼æ€§é«˜è†½å›ºé†‡è¡€ç—‡ã€æ··åˆå‹è¡€è„‚ç•°å¸¸ã€å‹•è„ˆç²¥ç‹€ç¡¬åŒ–å¿ƒè¡€ç®¡ç–¾ç—…é¢¨éšªé™ä½ |
| é æ¸¬æ–°é©æ‡‰ç—‡ | åŒåˆå­å®¶æ—æ€§é«˜è†½å›ºé†‡è¡€ç—‡ (homozygous familial hypercholesterolemia) |
| TxGNN é æ¸¬åˆ†æ•¸ | 99.48% |
| è­‰æ“šç­‰ç´š | L3 (å¤šç¯‡æ–‡ç»æ”¯æŒï¼ŒçœŸå¯¦ä¸–ç•Œæ•¸æ“š) |
| å°ç£ä¸Šå¸‚ | å·²ä¸Šå¸‚ |
| è¨±å¯è­‰æ•¸ | 1 |
| å»ºè­°æ±ºç­– | Go |





## é æ¸¬é©æ‡‰ç—‡è©³ç´°åˆ†æ

<details class="indication-section" open>
<summary>
<span class="indication-name">1. hyperthyroidism</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.61%</span> <span class="primary-badge">ä¸»è¦åˆ†æ</span>
</summary>
<div class="indication-content">

<h3>ç‚ºä»€éº¼é€™å€‹é æ¸¬åˆç†ï¼Ÿ</h3>

<p><p class="key-answer" data-question="é€™å€‹è—¥ç‰©çš„ä½œç”¨æ©Ÿè½‰æ˜¯ä»€éº¼ï¼Ÿ"></p>
<p>Bempedoic acid é€éæŠ‘åˆ¶ ATP æª¸æª¬é…¸è£‚è§£é…¶ (ACL) é™ä½è†½å›ºé†‡åˆæˆï¼Œä½œç”¨ä½é»åœ¨ HMG-CoA é‚„åŸé…¶çš„ä¸Šæ¸¸ã€‚å° HoFH æ‚£è€…çš„é—œéµå„ªå‹¢ï¼š</p>
<ol>
<li><strong>é LDL å—é«”ä¾è³´æ©Ÿåˆ¶</strong>ï¼šHoFH æ‚£è€… LDL å—é«”åŠŸèƒ½ç¼ºææˆ–ç¼ºå¤±ï¼Œå‚³çµ± statin å’Œ PCSK9 æŠ‘åˆ¶åŠ‘æ•ˆæœå—é™</li>
<li><strong>èˆ‡ç¾æœ‰ç™‚æ³•å”åŒ</strong>ï¼šå¯èˆ‡ statinã€ezetimibeã€PCSK9 æŠ‘åˆ¶åŠ‘ç­‰åˆä½µä½¿ç”¨</li>
<li><strong>ä¸ä¾è³´è‚Œè‚‰ä»£è¬</strong>ï¼šä½œç‚ºå‰è—¥åƒ…åœ¨è‚è‡Ÿæ´»åŒ–ï¼Œä¸æœƒåœ¨è‚Œè‚‰ç´°èƒä¸­æ´»åŒ–ï¼Œæ¸›å°‘è‚Œè‚‰ç›¸é—œå‰¯ä½œç”¨</li>
</ol>
<p></p></p>

<p><div class="key-takeaway"></p>
<p>æ­¤é æ¸¬åŸºæ–¼è—¥ç‰©çš„ä½œç”¨æ©Ÿè½‰ï¼Œèˆ‡ç¾æœ‰è‡¨åºŠè­‰æ“šæ–¹å‘ä¸€è‡´ã€‚</p>

<h3>è‡¨åºŠè©¦é©—</h3>

<p>ç›®å‰ç„¡é‡å°æ­¤ç‰¹å®šé©æ‡‰ç—‡çš„è‡¨åºŠè©¦é©—ç™»è¨˜ã€‚</p>

<h3>ç›¸é—œæ–‡ç»</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/40549098/" target="_blank">40549098</a></td><td>2025</td><td>Article</td><td>Drugs</td><td>Tiratricol: First Approval.</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">2. resistance to thyroid hormone due to a mutation in thyroid hormone receptor beta</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.58%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">3. malignant catarrh</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.58%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">4. infectious bovine rhinotracheitis</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.58%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">5. cytomegalovirus infection</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.53%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">6. homozygous familial hypercholesterolemia</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.48%</span>
</summary>
<div class="indication-content">

<h3>ç›¸é—œæ–‡ç»ï¼ˆ17 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/33766264/" target="_blank">33766264</a></td><td>2021</td><td>Article</td><td>Journal of the American Colleg</td><td>New and Emerging Therapies for Reduction of LDL-Cholesterol and Apolipoprotein B...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/35466160/" target="_blank">35466160</a></td><td>2022</td><td>Article</td><td>Journal of atherosclerosis and</td><td>Advancements in the Treatment of Homozygous Familial Hypercholesterolemia.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/38576462/" target="_blank">38576462</a></td><td>2024</td><td>Article</td><td>American journal of preventive</td><td>The importance of LDL-C lowering in atherosclerotic cardiovascular disease preve...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/41274797/" target="_blank">41274797</a></td><td>2026</td><td>Article</td><td>Journal of clinical lipidology</td><td>Real-world evaluation of bempedoic acid use in patients with homozygous familial...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/41106315/" target="_blank">41106315</a></td><td>2025</td><td>Article</td><td>Experimental and molecular pat</td><td>Breaking barriers: Innovative therapies for managing homozygous familial hyperch...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/37979722/" target="_blank">37979722</a></td><td>2024</td><td>Article</td><td>Indian heart journal</td><td>Traditional and novel non-statin lipid-lowering drugs.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/37071085/" target="_blank">37071085</a></td><td>2024</td><td>Article</td><td>Cardiology in review</td><td>Evinacumab-dgnb (Evkeeza-REGN1500), A Novel Lipid-Lowering Therapy for Homozygou...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/34081216/" target="_blank">34081216</a></td><td>2021</td><td>Article</td><td>Current cardiology reports</td><td>Beyond Statins and PCSK9 Inhibitors: Updates in Management of Familial and Refra...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/29449335/" target="_blank">29449335</a></td><td>2018</td><td>Article</td><td>Arteriosclerosis, thrombosis, </td><td>Bempedoic Acid Lowers Low-Density Lipoprotein Cholesterol and Attenuates Atheros...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/35754818/" target="_blank">35754818</a></td><td>2022</td><td>Article</td><td>Frontiers in genetics</td><td>The Progression of Treatment for Refractory Hypercholesterolemia: Focus on the P...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/33016816/" target="_blank">33016816</a></td><td>2021</td><td>Article</td><td>Expert opinion on pharmacother</td><td>Advances with lipid-lowering drugs for pediatric patients with familial hypercho...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/39070027/" target="_blank">39070027</a></td><td>2024</td><td>Article</td><td>American journal of preventive</td><td>Advances in targeting LDL cholesterol: PCSK9 inhibitors and beyond.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/28884604/" target="_blank">28884604</a></td><td>2017</td><td>Article</td><td>Expert review of clinical phar</td><td>Novel treatment options for the management of heterozygous familial hypercholest...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/32243228/" target="_blank">32243228</a></td><td>2020</td><td>Article</td><td>Postgraduate medicine</td><td>Emerging lipid lowering agents targeting LDL cholesterol.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/34514551/" target="_blank">34514551</a></td><td>2022</td><td>Article</td><td>American journal of cardiovasc</td><td>Lipid-Lowering Drug Therapy: Critical Approach for Implementation in Clinical Pr...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/29424317/" target="_blank">29424317</a></td><td>2019</td><td>Article</td><td>Current vascular pharmacology</td><td>Novel Hypolipidaemic Drugs: Mechanisms of Action and Main Metabolic Effects.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/36213094/" target="_blank">36213094</a></td><td>2022</td><td>Article</td><td>Current cardiovascular risk re</td><td>New Strategies for Lowering Low Density Lipoprotein Cholesterol for Cardiovascul...</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">7. hyperthyroxinemia</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.34%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">8. drug-induced osteoporosis</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.21%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">9. multiple endocrine neoplasia</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.18%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">10. pregnancy associated osteoporosis</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.17%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>


## å°ç£ä¸Šå¸‚è³‡è¨Š
| è¨±å¯è­‰è™Ÿ | ä¸­æ–‡å“å | åŠ‘å‹ | è¨±å¯è­‰æŒæœ‰è€… | æ•ˆæœŸ |
|----------|----------|------|--------------|------|
| è¡›éƒ¨è—¥è¼¸å­—ç¬¬028817è™Ÿ | å¯§è„‚å¾·è†œè¡£éŒ 180æ¯«å…‹ | è†œè¡£éŒ  | å°ç£ç¬¬ä¸€ä¸‰å…± | 2029/11/05 |

## å®‰å…¨æ€§è€ƒé‡
- **Major äº¤äº’ä½œç”¨**ï¼š
  - é¡å›ºé†‡é¡ï¼šhydrocortisone, prednisone, prednisolone, methylprednisolone, dexamethasone, betamethasone, budesonide, deflazacort, fludrocortisone
  - Simvastatinï¼šå¢åŠ è‚Œç—…é¢¨éšªï¼ŒåŠ‘é‡éœ€é™åˆ¶åœ¨ 20mg
  - Levofloxacinï¼šå¢åŠ è‚Œè…±ç—…è®Šé¢¨éšª
- **Moderate äº¤äº’ä½œç”¨**ï¼š
  - Rosuvastatinï¼šå»ºè­°åŠ‘é‡ä¸è¶…é 40mg
  - å¤šç¨®å…¶ä»–è—¥ç‰©


### è—¥ç‰©-ç–¾ç—…æ³¨æ„äº‹é … (DDSI)

<div class="ddsi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a>ï¼ˆåŸæ–‡å…§å®¹è«‹åƒé–±è©²ç¶²ç«™ï¼‰</div>

**Hepatic Insufficiency** ğŸŸ¡ Moderate
- æ‡‰è¬¹æ…ä½¿ç”¨æœ¬è—¥ç‰©ã€‚å¯èƒ½éœ€è¦èª¿æ•´åŠ‘é‡ã€‚å¯èƒ½æœ‰åš´é‡ä¸è‰¯åæ‡‰ã€‚

**Hyperuricemia** ğŸŸ¡ Moderate
- æ‡‰è¬¹æ…ä½¿ç”¨æœ¬è—¥ç‰©ã€‚éœ€å®šæœŸç›£æ¸¬ã€‚

**è…è‡Ÿç–¾ç—…** ğŸŸ¡ Moderate
- æ‡‰è¬¹æ…ä½¿ç”¨æœ¬è—¥ç‰©ã€‚å¯èƒ½æœ‰åš´é‡ä¸è‰¯åæ‡‰ã€‚

**Tendon Injuries** ğŸŸ¡ Moderate
- å¿…è¦æ™‚æ‡‰åœæ­¢æ²»ç™‚ã€‚

## çµè«–èˆ‡ä¸‹ä¸€æ­¥
**æ±ºç­–ï¼šGo**
**ç†ç”±ï¼š** TxGNN çš„é æ¸¬å·²ç²å¾—å¤§é‡æ–‡ç»æ”¯æŒï¼ŒåŒ…æ‹¬ 2026 å¹´æœ€æ–°ç™¼è¡¨çš„çœŸå¯¦ä¸–ç•Œæ•¸æ“šç ”ç©¶ã€‚Bempedoic acid å° HoFH çš„ç™‚æ•ˆæ©Ÿè½‰æ˜ç¢ºï¼Œä¸”å·²æœ‰å¤šç¯‡ç¶œè¿°æ–‡ç« å°‡å…¶åˆ—ç‚º HoFH æ²»ç™‚é¸é …ä¹‹ä¸€ã€‚è—¥ç‰©å·²åœ¨å°ç£ä¸Šå¸‚ï¼Œå…·å‚™ç«‹å³è‡¨åºŠæ‡‰ç”¨çš„æ¢ä»¶ã€‚
**è‹¥è¦æ¨é€²éœ€è¦ï¼š**
1. èˆ‡å¿ƒè‡Ÿç§‘/è„‚è³ªé–€è¨ºåˆä½œï¼Œåœ¨ HoFH æ‚£è€…ä¸­é–‹å§‹ä½¿ç”¨
2. æ”¶é›†å°ç£ HoFH æ‚£è€…ä½¿ç”¨ç¶“é©—ï¼Œå»ºç«‹æœ¬åœŸæ•¸æ“š
3. è€ƒæ…®ç”³è«‹é©æ‡‰ç—‡æ“´å±•
4. æ³¨æ„èˆ‡ simvastatin çš„äº¤äº’ä½œç”¨ï¼Œé¿å…è¶…éå»ºè­°åŠ‘é‡

---

## ç›¸é—œè—¥ç‰©å ±å‘Š

- [Voriconazole]({{ "/drugs/voriconazole/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Pemetrexed]({{ "/drugs/pemetrexed/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Nepafenac]({{ "/drugs/nepafenac/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Amorolfine]({{ "/drugs/amorolfine/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Sulfamerazine]({{ "/drugs/sulfamerazine/" | relative_url }}) - è­‰æ“šç­‰ç´š L5

---

{% include ai-analysis.html %}

{% include social-share.html %}

## å¼•ç”¨æœ¬å ±å‘Š

å¦‚éœ€å¼•ç”¨æœ¬å ±å‘Šï¼Œè«‹ä½¿ç”¨ä»¥ä¸‹æ ¼å¼ï¼š

**APA æ ¼å¼ï¼š**
```
TwTxGNN. (2026). Bempedoic Acidè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š. https://twtxgnn.yao.care/drugs/bempedoic_acid/
```

**BibTeX æ ¼å¼ï¼š**
```bibtex
@misc{twtxgnn_bempedoic_acid,
  title = {Bempedoic Acidè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/bempedoic_acid/}
}
```

---

<div class="disclaimer">
<strong>å…è²¬è²æ˜</strong><br>
æœ¬å ±å‘Šåƒ…ä¾›å­¸è¡“ç ”ç©¶åƒè€ƒï¼Œ<strong>ä¸æ§‹æˆé†«ç™‚å»ºè­°</strong>ã€‚è—¥ç‰©ä½¿ç”¨è«‹éµå¾ªé†«å¸«æŒ‡ç¤ºï¼Œåˆ‡å‹¿è‡ªè¡Œèª¿æ•´ç”¨è—¥ã€‚ä»»ä½•è€è—¥æ–°ç”¨æ±ºç­–éœ€ç¶“éå®Œæ•´çš„è‡¨åºŠé©—è­‰èˆ‡æ³•è¦å¯©æŸ¥ã€‚
<br><br>
<small>æœ€å¾Œå¯©æ ¸ï¼š2026-02-20 | å¯©æ ¸è€…ï¼šTwTxGNN Research Team</small>
</div>

{% include giscus.html %}
